차세대 항암제의 게임 체인저, 에이비엘바이오의 이중항체 ADC가 여는 새로운 지평 > K-wave Trends

The key candidate substance that ABL Bio will highlight at this event is 'ABL209 (NEOK002).' This substance is a bispecific antibody-based ADC designed to simultaneously target two tumor antigens: Epidermal Growth Factor Receptor (EGFR) and Mucin 1 (MUC1). By combining this with a 'topoisomerase I inhibitor'—a payload with potent cytotoxic efficacy—the cancer-killing power has been dramatically increased. Currently, this substance has entered Phase 1 clinical trials through NEOK Bio, a subsidiary established by ABL Bio in the United States, and is in the process of having its competitiveness in the global market verified.

The core of this seminar lies in how the technical challenge of 'expanding the therapeutic window' has been solved. Conventional single-antibody ADCs rely on only one specific antigen, often leading to side effects because they cannot fully distinguish between cancer cells and healthy cells. In contrast, ABL209 utilizes the 'Grabody' platform—a bispecific antibody technology that selectively recognizes two antigens—to increase binding affinity to cancer cells while minimizing toxicity to healthy tissues. During the presentation, the company intends to directly address the skepticism of academia and the industry with technical data by disclosing detailed anti-tumor activity data and toxicity assessment results confirmed in the preclinical stage.

ABL Bio's progress goes beyond just introducing a single drug candidate. Led by CEO Sang-Hoon Lee, the company aims to secure a dominant position in the bispecific ADC field through the clinical development of not only ABL209 but also another pipeline, ABL206 (NEOK001). In particular, they are focusing their R&D capabilities on completely overcoming the limitations of single-targeting by expanding into next-generation technologies such as Dual Payload ADCs. This is evaluated as evidence that a Korean biotech company possesses the potential to lead the next-generation technological standards in the global anticancer drug market.

As the World ADC Korea event is a platform where global experts gather to share the latest technological trends, ABL Bio's presentation will be a critical turning point for international technical cooperation and partnership building. Currently, ABL Bio operates over 10 pipelines through a multinational clinical network spanning the U.S., China, Australia, and Korea, securing a vast clinical database. This extensive research data will play a decisive role in proving that ABL209 is more than just a theoretical concept, but a commercially viable therapeutic, and is expected to attract interest from global pharmaceutical companies for investment and co-development.

Meanwhile, among the recent briefings in the pharmaceutical and biotech industry, various market changes are being observed, such as personnel reshuffles like the recruitment of CTO Inadan at Rokit Healthcare, or the launch of large-capacity packages for Boryung Consumer Healthcare's Gelfos M. However, even amidst this news, ABL Bio's technological challenge stands out as the clearest milestone showing how advanced biotech platform technology creates clinical value. Their journey of independently conducting everything from basic research to Phase 1 clinical trials to perfect their technology suggests that the Korean pharmaceutical and biotech industry has entered a stage of creating innovative modalities, moving beyond simple imitation.